Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04761601
Status:
TERMINATED
Last Update Posted:
2024-03-13
First Post:
2021-02-16
Brief Title:
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Sponsor:
1200 Pharma LLC
Organization:
1200 Pharma LLC
Study Overview
Official Title:
A Phase 1 First in Human Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Stopped for strategic business reasons The decision to stop the study was not connected to any safety concerns or new risk associated with the study product intervention or procedures
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This first-in-human study will evaluate the safety tolerability pharmacokinetics and antitumor activity of UCT-01-097 in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None